Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

Shots:

  • Vertex signs a licensing agreement with CRISPR to develop & discover gene editing therapies for DMD and DM1. CRISPR to get $1B, as total deal value including $175M upfront, milestones and royalties on sales. Vertex to get exclusive WW rights for IPR of gene editing therapies including foundational CRISPR/Cas9 technology, novel endonucleases, single and double cut guide RNAs, and AAV vectors
  • Vertex to take care of all cost related to research, development, manufacturing, and commercialization of products and the companies will share cost for specified guide RNA research conducted by CRISPR. CRISPR also holds an option to co-develop & co-commercialize all DM1 products in exchange of milestones and royalties at IND filling
  • Additionally, Vertex acquires Exonics Therapeutics, in all stock transaction making total deal value $1B including $245M upfront and milestones for DMD and DM1 programs. Both the transactions are expected to close in Q3’19

Click here to read full press release/ article | Ref: Vertex | Image: Behnace